Meet Our Management Team

Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.

PAUL J. CROWE

Chairman and CEO

Mr. Crowe founded NuView Life Sciences in 2005 and serves as its Chairman and Chief Executive Officer. Mr. Crowe’s experience includes start-up and early-stage healthcare company development, strategic planning, capital formation, M&A, and public offerings. Mr. Crowe’s career includes senior executive sales and management positions for domestic and multi-national healthcare companies who introduced (a) diagnostic ultrasound in 1973 for Rohe Ultrasound – NV Philips Medical Systems; (b) nuclear magnetic resonance (NMR / MRI) in 1983 for Diasonics NMR Inc.; and (c) mobile positron emission tomography (PET) in 1999 for Mobile P.E.T. Systems Inc., Between 1986 and 1999 Mr. Crowe developed and operated outpatient medical service provider businesses, including diagnostic imaging facilities and gamma knife radio surgery facilities, and currently serves on the Board of Radiosurgical Centers of San Diego located at Scripps Memorial Hospital.

E. ROBERT WASSMAN M.D.

Chief Science Officer

Dr. Wassman has pioneered the introduction of genetic testing and personalized medicine for over 35-years. His focus has been on the translation and delivery of cutting-edge diagnostic technology to clinical service in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and Next Generation DNA sequencing spanning clinical disciplines of reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism. His strategic insights, deep knowledge, and “quick study” abilities have enable him to achieve numerous “firsts” in many areas.
He has served as Chief Medical Officer for multiple companies in this space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, Alfigen. He has co-founded several successful ventures, and served as a consultant to a wide variety of entities ranging from large and small clinical laboratories, IVD and Biotech companies, investor groups, regulatory agencies, payers and legal firms.
In addition to clinical and technical expertise he has laboratory and general operational, business development, medical affairs/marketing and sales experience. He had formal training and both public and private sector experience in reimbursement and managed care. He has had international experience in Europe, Japan and China.
He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.
Currently he co-directs a novel reproductive genetics lab, Predictive Laboratories in Salt Lake City, and serves as a senior executive advisor to a number of start-ups and other clients. He serves on the Board of Directors and SAB of the TESS Foundation, a non-profit focused on treatments for epilepsy and symptoms of SLC13A5.

Jill Helmke, D.Ph,N.Ph.

Director Clinical Trial Operations

Jill S. Helmke, Certified Nuclear Pharmacist and Doctor of Pharmacy, comes to NuView Life Sciences, with over 25 years of pharmacy experience ranging from outpatient pharmacy to clinical research. A graduate of The Ohio State University, she also completed a specialty in Nuclear Medicine. In addition, she has degrees in Business Management and Music from Baldwin Wallace University. Dr. Helmke practiced nuclear medicine for 15 years at Cardinal Health and Vanderbilt University Medical Center, specializing in Positron Emission Tomography (PET). While at Vanderbilt, she branched into Biomedical Informatics wherein she focused on pediatric drug formulations, as well as compounding research and development. A major contributor to STEPStools (Safety through Electronic Prescribing System Tools), Dr. Helmke presented her research to the American Academy of Pediatrics in Washington D.C. and has received national recognition for her efforts in Biomedical Informatics. After relocating to Park City, UT, Dr. Helmke continued her Biomedical Informatics research with the University of Utah. Subsequently, she conducted Phase I-IV clinical drug trials with PRA Health Sciences.

THOMAS BROWN

Chief Financial Officer

Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets as well as businesses. Mr. Brown is the founding partner of three investment banking firms, a private equity firm and an investment management firm. Mr. Brown has served as the CFO of several public and private companies as well as non-profit organizations focused on coordinating the reporting and management of the financial infrastructure of emerging growth ventures and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies. Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.

STEVEN J. DAVIS

General Counsel

Mr. Davis is the founder of SD Law Group, a corporate and securities law firm located in San Diego, California, which was founded in 2005.

Mr. Davis has worked with a wide variety of clients in the areas of corporate, securities and business law since 1992 and has been responsible for over $1 billion in transactions. He is also on the Board of Directors of Theragene Pharmaceuticals, Inc. and Philter Labs, Inc., and was on the Board of Directors and Audit, Compensation, Nominating Committees (Chairman) and Special Committee (Chairman) of Telanetix, Inc., a publicly traded telecommunications company which was sold to InterMedia (an Oak Hill Capital portfolio company). He served as General Counsel and an executive officer of Molecular Imaging Corporation, a publicly traded healthcare company, and as in-house counsel for Leap Wireless International, a publicly traded wireless carrier. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a large full-service law firm, where he advised both private and public clients in a variety of transactions.

Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.

He has also co-founded Clonatec, one of the first French biotech companies.